Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D.Phil., Chief Executive Officer of Idera, will present at the 16^th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. EST at the Waldorf Astoria in New York City.

A live audio webcast of the presentation will be available in the Investors and Media section of Idera's website at www.iderapharma.com or at the link http://www.veracast.com/webcasts/bio/ceoinvestor2014/52236438008.cfm. An archived version will also be available on the Company's website after the event for 90 days.

About Idera Pharmaceuticals, Inc.

Idera’s proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). Idera is developing these therapeutics for the treatment of genetically defined forms of B-cell lymphoma and for autoimmune diseases with orphan indications. In addition to its TLR programs, Idera is developing gene silencing oligonucleotides that it has created using its proprietary technology, to inhibit the production of disease-associated proteins by targeting RNA.

Source: Idera Pharmaceuticals, Inc.

Investor Contact:
Stern Investor Relations, Inc.
Sarah McCabe, 267-909-9237
sarah@sternir.com